好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Reversing Metabolomic Aging in Multiple Sclerosis: Effects of Fasting Mimicking Diets
Multiple Sclerosis
S33 - Multiple Sclerosis: Biomarkers in MS (4:18 PM-4:30 PM)
005

Biological aging, a better indicator of health than chronological age, may be reversible with targeted interventions. Fasting-mimicking diets such as intermittent calorie restriction (CR) and ketogenic diets (KD) improve immune function, reduce inflammation, and improve clinical outcomes in PwMS. However, it remains unclear whether these improvements are reflected by changes in biological age, as captured using metabolomic profiling. 

To evaluate whether biological aging, as measured by metabolomic age, in people with multiple sclerosis (PwMS) can be reversed through dietary interventions.

Plasma samples from two previously conducted dietary intervention studies, with slightly different sets of measured metabolites on distinct platforms, were used to calculate metabolomic age, pre- and post-intervention. The metabolomic age clock, based on plasma metabolomic profiles from 11,977 healthy individuals, was utilized. In the first study, 36 people with relapsing-remitting MS (RRMS) were randomized into three groups for eight weeks: daily CR (22% caloric reduction), intermittent CR (75% reduction for 2 days/week), or a weight-stable control diet (100% of daily caloric needs). In the second study, 39 RRMS patients followed a KD for six months, and metabolomic age was measured before and after intervention. Between-group and within-person comparisons were performed using models allowing for correlated data.

Participants randomized to the intermittent CR diet experienced a significant reduction in metabolomic age compared to those on the weight-stable control diet (mean difference in metabolomic age for intermittent CR vs. control diets per week: -1.25 years; 95% CI: -2.46, -0.04 years; p=0.04). Additionally, adherence to the KD for six months resulted in a mean reduction of 1.12 years per month (95% CI: 0.36, 1.89 years; p=0.007) in metabolomic age.

Intermittent calorie restriction and ketogenic diets significantly reduced metabolomic age in people with RRMS, demonstrating that biological aging is modifiable through lifestyle interventions.

Authors/Disclosures
Fatemeh Siavoshi, MD
PRESENTER
Dr. Siavoshi has nothing to disclose.
Matthew Smith Matthew Smith has nothing to disclose.
G. Brett Moreau, PhD Dr. Moreau has nothing to disclose.
James N. Brenton, MD Dr. Brenton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for I-ACT on a Novartis sponsored project. The institution of Dr. Brenton has received research support from NIH/NINDS. The institution of Dr. Brenton has received research support from Autoimmune Encephalitis Alliance. Dr. Brenton has received publishing royalties from a publication relating to health care. Dr. Brenton has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with Department of Defense. Dr. Brenton has received personal compensation in the range of $0-$499 for serving as a Grant Reviewer with NIH. Dr. Brenton has received personal compensation in the range of $0-$499 for serving as a Grant Reviewer with FDA.
Ellen M. Mowry, MD, FAAN (Johns Hopkins University) Dr. Mowry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BeCareLink, LLC. The institution of Dr. Mowry has received research support from Biogen. The institution of Dr. Mowry has received research support from Genentech. Dr. Mowry has received publishing royalties from a publication relating to health care.
Kathryn Fitzgerald, PhD (Johns Hopkins University) The institution of Dr. Fitzgerald has received research support from NIH. The institution of Dr. Fitzgerald has received research support from National MS Society.
Pavan Bhargava, MD, FAAN (Johns Hopkins University) The institution of Dr. Bhargava has received research support from EMD Serono. The institution of Dr. Bhargava has received research support from Amylyx pharmaceuticals. The institution of Dr. Bhargava has received research support from Genentech. The institution of Dr. Bhargava has received research support from GSK.